PDCD1 and non-small cell lung carcinoma: Two other anti-PD-1/PD-L1 ICIs—cemiplimab (anti-PD-1) and avelumab (anti-PD-L1)—are not yet approved for NSCLC in the U.S. In a recent study, cemiplimab led to an approximately 50% response rate for advanced cutaneous squamous-cell carcinoma, and was approved for this purpose by the FDA in September 2018 [56].